or Try an Advanced Search...

    Astellas Pharma Stocks List

    Symbol Grade Name % Change
    AMGN B Amgen Inc. -0.71
    CYTK F Cytokinetics, Incorporated -0.65
    RPRX F Royalty Pharma plc -2.19
    IRWD F Ironwood Pharmaceuticals, Inc. -2.41
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Biotechnology Human Therapeutic Products Neuroscience Pharmaceutical Products Therapeutic Products Amyotrophic Lateral Sclerosis Biopharmaceutical Biopharmaceutical Products Blood Cells Bone Bone Disease Cancer Care Cardiovascular Disease Central Nervous System Disorders Chronic Idiopathic Constipation Clinic Clinical Development Constipation Cytokine Dialysis

    Related ETFs - A few ETFs which own one or more of the above listed Astellas Pharma stocks.

    Symbol Grade Name Weight
    BBH B Market Vectors Biotech ETF 17.18
    IBBQ B Invesco Nasdaq Biotechnology ETF 11.42
    IBB B iShares Nasdaq Biotechnology Index Fund 10.13
    BIS F ProShares UltraShort Nasdaq Biotechnology 8.38
    BIB C ProShares Ultra Nasdaq Biotechnology 7.95
    View all Astellas Pharma ETFs...
    Compare ETFs
    Compare BBH to IBB Compare IBBQ to BIB Compare IBBQ to BIS

        Astellas Pharma Stocks Recent News

        Date Stock Title
        May 17 AMGN 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
        May 17 CYTK Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself
        May 17 AMGN Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
        May 17 AMGN Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
        May 17 AMGN FDA approves Amgen drug for tough-to-treat form of lung cancer
        May 17 CYTK Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
        May 17 AMGN Amgen’s IMDELLTRA receives FDA approval for lung cancer treatment
        May 16 AMGN FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
        May 16 AMGN Amgen wins FDA nod for new lung cancer therapy
        May 16 AMGN KRAS inhibitors: The next frontier beckons
        May 15 AMGN AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
        May 15 CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
        May 14 AMGN Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
        May 13 CYTK Health Care Roundup: Market Talk
        May 13 CYTK Cytokinetics Reveals More From The Study That Boosted Shares 83%
        May 13 CYTK Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
        May 13 CYTK Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
        May 13 RPRX Royalty Pharma to Present at Upcoming Investor Conferences
        May 13 AMGN The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs
        May 12 RPRX Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Biotechnology Human Therapeutic Products Neuroscience Pharmaceutical Products Therapeutic Products Amyotrophic Lateral Sclerosis Biopharmaceutical Biopharmaceutical Products Blood Cells Bone Bone Disease Cancer Care Cardiovascular Disease Central Nervous System Disorders Chronic Idiopathic Constipation Clinic Clinical Development Constipation Cytokine Dialysis
        Astellas Pharma

        Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha).
        Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu.

        More about Astellas Pharma
        Browse All Tags